Drugs / TAH-1005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05275946 | Nov 2021 → Dec 2024 | thyroid cancer | Osaka University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAH-1005 | “Targeted Alpha Therapy Drug TAH-1005 ([211At] NaAt)” NCT05275946 ↗ |
| Known as | [211At] NaAt | “Targeted Alpha Therapy Drug TAH-1005 ([211At] NaAt)” NCT05275946 ↗ |
| Route | Intravenous | “Single intravenous administration” NCT05275946 ↗ |